Phase I-II trial of interferon-α(2b) by continuous subcutaneous infusion over 28 days

Robert T Dorr, S. E. Salmon, A. Robertone, E. Bonnem

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Interferon-α(2b) (IFN-α) was administered by continuous subcutaneous (s.c.) infusion to 23 patients with hematologic malignancies or metastatic solid tumors: 5 patients with multiple myeloma, 3 with malignant melanoma, 2 with chronic myelogenous leukemia (CML), 10 patients with renal cell cancer, and 3 patients with other solid tumors. Drug was delivered by continuous s.c. infusion for 28 days (1 cycle) at daily dose levels of 0.7, 1.4, 2.5, 3.6, or 5.0 x 106 IU/m2 to 3, 3, 3, 8, and 6 patients, respectively. At the highest dose level, a severe flu-like syndrome was seen in 3 patients and severe gastrointestinal toxicity in 2 patients. The maximally tolerated dose (MTD) was 3.6 x 106 IU/m2.day and the principal toxicity was a mild to moderate flu-like syndrome. Local skin reactions were occasionally noted at all dose levels if the s.c. needle site was not rotated every 3-4 days. At dose levels of 2.5-3.6 x 106 IU/m2.day, IFN-α serum levels at steady state ranged from 19 to 61 IU/ml. The time to achieve steady-state conditions ranged from 40 to 72 h and at steady state, 24 h area under the concentration time curve (AUC(24 h)) ranged from 480 to 1,464 IU/ml.h. Objective responses were seen 3 of 17 evaluable patients: 1/7 in renal cell cancer (14%); 1/2 in CML and in one patient with ependymoma. Remissions lasted 4, 8, and 15 months in renal cell, CML, and ependymoma, respectively. Continuous s.c. IFN-α produces objective responses and higher cumulative serum drug exposures than bolus methods of drug administration, with an MTD for the continuous s.c. route being half that of daily bolus s.c. dosing. The recommended dose for phase II studies is 2.5 x 106 IU/m2.day for 28 days.

Original languageEnglish (US)
Pages (from-to)717-725
Number of pages9
JournalJournal of Interferon Research
Volume8
Issue number6
StatePublished - 1988

Fingerprint

Subcutaneous Infusions
Interferons
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Ependymoma
Maximum Tolerated Dose
Renal Cell Carcinoma
Pharmaceutical Preparations
Hematologic Neoplasms
Serum
Multiple Myeloma
Area Under Curve
Needles
Melanoma
Neoplasms
Kidney
Skin

ASJC Scopus subject areas

  • Immunology
  • Virology

Cite this

Phase I-II trial of interferon-α(2b) by continuous subcutaneous infusion over 28 days. / Dorr, Robert T; Salmon, S. E.; Robertone, A.; Bonnem, E.

In: Journal of Interferon Research, Vol. 8, No. 6, 1988, p. 717-725.

Research output: Contribution to journalArticle

Dorr, Robert T ; Salmon, S. E. ; Robertone, A. ; Bonnem, E. / Phase I-II trial of interferon-α(2b) by continuous subcutaneous infusion over 28 days. In: Journal of Interferon Research. 1988 ; Vol. 8, No. 6. pp. 717-725.
@article{02087c928efb443c813adf71012cd9c3,
title = "Phase I-II trial of interferon-α(2b) by continuous subcutaneous infusion over 28 days",
abstract = "Interferon-α(2b) (IFN-α) was administered by continuous subcutaneous (s.c.) infusion to 23 patients with hematologic malignancies or metastatic solid tumors: 5 patients with multiple myeloma, 3 with malignant melanoma, 2 with chronic myelogenous leukemia (CML), 10 patients with renal cell cancer, and 3 patients with other solid tumors. Drug was delivered by continuous s.c. infusion for 28 days (1 cycle) at daily dose levels of 0.7, 1.4, 2.5, 3.6, or 5.0 x 106 IU/m2 to 3, 3, 3, 8, and 6 patients, respectively. At the highest dose level, a severe flu-like syndrome was seen in 3 patients and severe gastrointestinal toxicity in 2 patients. The maximally tolerated dose (MTD) was 3.6 x 106 IU/m2.day and the principal toxicity was a mild to moderate flu-like syndrome. Local skin reactions were occasionally noted at all dose levels if the s.c. needle site was not rotated every 3-4 days. At dose levels of 2.5-3.6 x 106 IU/m2.day, IFN-α serum levels at steady state ranged from 19 to 61 IU/ml. The time to achieve steady-state conditions ranged from 40 to 72 h and at steady state, 24 h area under the concentration time curve (AUC(24 h)) ranged from 480 to 1,464 IU/ml.h. Objective responses were seen 3 of 17 evaluable patients: 1/7 in renal cell cancer (14{\%}); 1/2 in CML and in one patient with ependymoma. Remissions lasted 4, 8, and 15 months in renal cell, CML, and ependymoma, respectively. Continuous s.c. IFN-α produces objective responses and higher cumulative serum drug exposures than bolus methods of drug administration, with an MTD for the continuous s.c. route being half that of daily bolus s.c. dosing. The recommended dose for phase II studies is 2.5 x 106 IU/m2.day for 28 days.",
author = "Dorr, {Robert T} and Salmon, {S. E.} and A. Robertone and E. Bonnem",
year = "1988",
language = "English (US)",
volume = "8",
pages = "717--725",
journal = "Journal of Interferon Research",
issn = "0197-8357",
publisher = "Mary Ann Liebert Inc.",
number = "6",

}

TY - JOUR

T1 - Phase I-II trial of interferon-α(2b) by continuous subcutaneous infusion over 28 days

AU - Dorr, Robert T

AU - Salmon, S. E.

AU - Robertone, A.

AU - Bonnem, E.

PY - 1988

Y1 - 1988

N2 - Interferon-α(2b) (IFN-α) was administered by continuous subcutaneous (s.c.) infusion to 23 patients with hematologic malignancies or metastatic solid tumors: 5 patients with multiple myeloma, 3 with malignant melanoma, 2 with chronic myelogenous leukemia (CML), 10 patients with renal cell cancer, and 3 patients with other solid tumors. Drug was delivered by continuous s.c. infusion for 28 days (1 cycle) at daily dose levels of 0.7, 1.4, 2.5, 3.6, or 5.0 x 106 IU/m2 to 3, 3, 3, 8, and 6 patients, respectively. At the highest dose level, a severe flu-like syndrome was seen in 3 patients and severe gastrointestinal toxicity in 2 patients. The maximally tolerated dose (MTD) was 3.6 x 106 IU/m2.day and the principal toxicity was a mild to moderate flu-like syndrome. Local skin reactions were occasionally noted at all dose levels if the s.c. needle site was not rotated every 3-4 days. At dose levels of 2.5-3.6 x 106 IU/m2.day, IFN-α serum levels at steady state ranged from 19 to 61 IU/ml. The time to achieve steady-state conditions ranged from 40 to 72 h and at steady state, 24 h area under the concentration time curve (AUC(24 h)) ranged from 480 to 1,464 IU/ml.h. Objective responses were seen 3 of 17 evaluable patients: 1/7 in renal cell cancer (14%); 1/2 in CML and in one patient with ependymoma. Remissions lasted 4, 8, and 15 months in renal cell, CML, and ependymoma, respectively. Continuous s.c. IFN-α produces objective responses and higher cumulative serum drug exposures than bolus methods of drug administration, with an MTD for the continuous s.c. route being half that of daily bolus s.c. dosing. The recommended dose for phase II studies is 2.5 x 106 IU/m2.day for 28 days.

AB - Interferon-α(2b) (IFN-α) was administered by continuous subcutaneous (s.c.) infusion to 23 patients with hematologic malignancies or metastatic solid tumors: 5 patients with multiple myeloma, 3 with malignant melanoma, 2 with chronic myelogenous leukemia (CML), 10 patients with renal cell cancer, and 3 patients with other solid tumors. Drug was delivered by continuous s.c. infusion for 28 days (1 cycle) at daily dose levels of 0.7, 1.4, 2.5, 3.6, or 5.0 x 106 IU/m2 to 3, 3, 3, 8, and 6 patients, respectively. At the highest dose level, a severe flu-like syndrome was seen in 3 patients and severe gastrointestinal toxicity in 2 patients. The maximally tolerated dose (MTD) was 3.6 x 106 IU/m2.day and the principal toxicity was a mild to moderate flu-like syndrome. Local skin reactions were occasionally noted at all dose levels if the s.c. needle site was not rotated every 3-4 days. At dose levels of 2.5-3.6 x 106 IU/m2.day, IFN-α serum levels at steady state ranged from 19 to 61 IU/ml. The time to achieve steady-state conditions ranged from 40 to 72 h and at steady state, 24 h area under the concentration time curve (AUC(24 h)) ranged from 480 to 1,464 IU/ml.h. Objective responses were seen 3 of 17 evaluable patients: 1/7 in renal cell cancer (14%); 1/2 in CML and in one patient with ependymoma. Remissions lasted 4, 8, and 15 months in renal cell, CML, and ependymoma, respectively. Continuous s.c. IFN-α produces objective responses and higher cumulative serum drug exposures than bolus methods of drug administration, with an MTD for the continuous s.c. route being half that of daily bolus s.c. dosing. The recommended dose for phase II studies is 2.5 x 106 IU/m2.day for 28 days.

UR - http://www.scopus.com/inward/record.url?scp=0024244243&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024244243&partnerID=8YFLogxK

M3 - Article

C2 - 3230330

AN - SCOPUS:0024244243

VL - 8

SP - 717

EP - 725

JO - Journal of Interferon Research

JF - Journal of Interferon Research

SN - 0197-8357

IS - 6

ER -